ArticleOpen forum infectious diseases2022
Economic Burden of Fungal Diseases in the United States.
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed.
- Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized Trials.Open forum infectious diseases · 2026Trial
- Outbreaks of fluconazole-resistant Candida parapsilosis are driven by low-biofilm-producing isolates that emerge under host selection.PLoS biology · 2026Article
- Active Surveillance for Invasive Mold Disease - Four Hospitals, Atlanta, Georgia, 2020-2024.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2026Article
- Contribution of fungal diseases to the U.S. chronic disease burden.Clinical microbiology reviews · 2026Review
- Outcomes and Predictors of Fungal Necrotizing Soft Tissue Infections.Surgical infections · 2026Article
- The rheological properties ofBiofilm · 2026Article
- Characterization ofJournal of medical microbiology · 2026Article
- A comparative analysis estimating aspergillosis and histoplasmosis encounters among inpatients in the United States using multi-regional electronic health record and National Discharge Data, 2014-2020.AJE advances : research in epidemiology · 2026Article
- Review
- Article
- Utilization of Intensive Care Interventions in Critically Ill Patients With Candidemia Versus Bacteremia: A Multicenter Retrospective Cohort Study.Critical care medicine · 2026Article
- Genetic Insights into the Rheological Phenotype of Candida albicans Biofilms.Research square · 2026Article
- Coccidioidomycosis-Associated Hospitalizations, United States, 2016-2021.Open forum infectious diseases · 2025Article
- Mapping the Geographic Distribution of Dimorphic Mycoses Using a US Commercial Insurance Database.Open forum infectious diseases · 2025Article
- Dermatophyte-Selective Imidazole-Thiosemicarbazides: Potent In Vitro Activity AgainstInternational journal of molecular sciences · 2025Article
- The Use of Genetics and Immunology in the Diagnosis and Care of Advanced Coccidioidomycosis: Where Are We Going?Journal of fungi (Basel, Switzerland) · 2025Article
- Healthcare Resource Utilization, Treatment Costs, and Mortality in Patients with Malignancies or Transplantation Who Develop Invasive Aspergillosis.Journal of fungi (Basel, Switzerland) · 2025Article
- The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release.PLoS pathogens · 2025Article
- Article
- Epidemiology of Candidemia in Children and Neonates in Korea, 2009-2018: A Multi-Center Study.Journal of Korean medical science · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conservatively estimated the US economic burden of fungal diseases as $11.5 billion in 2019: direct medical costs ($7.5 billion), productivity loss due to absenteeism ($870 million), and premature deaths ($3.2 billion). An alternative "value of statistical life" approach yielded >$48 billion. These are likely underestimates given underdiagnosis and underreporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.